NCT05962151Phase 2Completed

Refractory Chronic Cough Improvement Via NAL ER (RIVER)

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2025-01-06Actual

Enrollment · participants66Actual

Source updated2026-03-30Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Refractory Chronic Cough

Treatments or interventions studied

NAL ERDrugAlso known as Nalbuphine
PlaceboDrug

Primary outcomes · main study measures

measure: Relative Change From Baseline in 24-hour Cough Frequency at Day 21; description: Relative change in 24-hour (combined daytime and nighttime) cough frequency (coughs per hour) from baseline was assessed. Assessment was done using objective digital cough monitoring. Baseline was defined as the last non-missing assessment, prior to the first dose of study drug.; timeFrame: Baseline, Day 21

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history